fulvestrant has been researched along with interleukin-8 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awad, EM; Bochkov, VN; Demyanets, S; Dietrich, W; Hohensinner, PJ; Huber, K; Kastl, SP; Kaun, C; Maurer, G; Pfaffenberger, S; Rega, G; Speidl, WS; Tschugguel, W; Weiss, TW; Wojta, J | 1 |
| Gao, Y; Ho, SM; Lau, KM; Leung, YK; Zhang, X | 1 |
2 other study(ies) available for fulvestrant and interleukin-8
| Article | Year |
|---|---|
The estrogen metabolite 17beta-dihydroequilenin counteracts interleukin-1alpha induced expression of inflammatory mediators in human endothelial cells in vitro via NF-kappaB pathway.
Topics: Anti-Inflammatory Agents; Base Sequence; Cells, Cultured; Chemokine CCL2; Dose-Response Relationship, Drug; Endothelial Cells; Equilin; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Fulvestrant; Humans; Interleukin-1; Interleukin-6; Interleukin-8; Molecular Sequence Data; NF-kappa B; RNA, Messenger | 2006 |
ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Estradiol; Estrogen Receptor beta; Fulvestrant; Gene Expression Regulation, Neoplastic; Growth Differentiation Factor 1; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-12; Interleukin-8; Male; NF-kappa B; Prostatic Neoplasms; Receptor Protein-Tyrosine Kinases | 2006 |